377 related articles for article (PubMed ID: 34115611)
1. Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis.
Zhang L; Hou J; Li J; Su SS; Xue S
Aging (Albany NY); 2021 Jun; 13(13):17914-17929. PubMed ID: 34115611
[TBL] [Abstract][Full Text] [Related]
2. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
[TBL] [Abstract][Full Text] [Related]
3. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis.
Zheng Q; Yang H; Fu X; Huang Y; Wei R; Wang Y; Liu YN; Liu WJ
Nephrol Dial Transplant; 2021 Aug; 36(9):1603-1615. PubMed ID: 33051677
[TBL] [Abstract][Full Text] [Related]
5. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
Akizawa T; Iwasaki M; Otsuka T; Reusch M; Misumi T
Adv Ther; 2019 Jun; 36(6):1438-1454. PubMed ID: 30953333
[TBL] [Abstract][Full Text] [Related]
6. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.
Fishbane S; El-Shahawy MA; Pecoits-Filho R; Van BP; Houser MT; Frison L; Little DJ; Guzman NJ; Pergola PE
J Am Soc Nephrol; 2021 Mar; 32(3):737-755. PubMed ID: 33568383
[TBL] [Abstract][Full Text] [Related]
7. Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.
Akizawa T; Tanaka-Amino K; Otsuka T; Yamaguchi Y
Am J Nephrol; 2021; 52(9):702-713. PubMed ID: 34628408
[TBL] [Abstract][Full Text] [Related]
8. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.
Chen N; Hao C; Peng X; Lin H; Yin A; Hao L; Tao Y; Liang X; Liu Z; Xing C; Chen J; Luo L; Zuo L; Liao Y; Liu BC; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
N Engl J Med; 2019 Sep; 381(11):1001-1010. PubMed ID: 31340089
[TBL] [Abstract][Full Text] [Related]
9. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
Akizawa T; Otsuka T; Reusch M; Ueno M
Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.
Provenzano R; Szczech L; Leong R; Saikali KG; Zhong M; Lee TT; Little DJ; Houser MT; Frison L; Houghton J; Neff TB
Clin J Am Soc Nephrol; 2021 Aug; 16(8):1190-1200. PubMed ID: 34362786
[TBL] [Abstract][Full Text] [Related]
11. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.
Liu J; Zhang A; Hayden JC; Bhagavathula AS; Alshehhi F; Rinaldi G; Kontogiannis V; Rahmani J
Pharmacol Res; 2020 May; 155():104747. PubMed ID: 32171893
[TBL] [Abstract][Full Text] [Related]
12. Impact of C-reactive protein on the effect of Roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials.
Luo X; Li G; Yang H; Chen L; Gao Y; Cong J; Luo H; Zhang W
BMC Nephrol; 2024 Feb; 25(1):47. PubMed ID: 38311719
[TBL] [Abstract][Full Text] [Related]
13. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
Akizawa T; Ueno M; Shiga T; Reusch M
Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
[TBL] [Abstract][Full Text] [Related]
14. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116
[TBL] [Abstract][Full Text] [Related]
15. Development of a health economic model to evaluate the cost-effectiveness of roxadustat in treating anemia associated with non-dialysis-dependent chronic kidney disease.
Mata Lorenzo M; Ali M; Mealing S; Moss J
J Med Econ; 2023; 26(1):1250-1260. PubMed ID: 37752891
[TBL] [Abstract][Full Text] [Related]
16. Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
Barratt J; Dellanna F; Portoles J; Choukroun G; De Nicola L; Young J; Dimković N; Reusch M
Adv Ther; 2023 Apr; 40(4):1546-1559. PubMed ID: 36749544
[TBL] [Abstract][Full Text] [Related]
17. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
[TBL] [Abstract][Full Text] [Related]
18. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
Csiky B; Schömig M; Esposito C; Barratt J; Reusch M; Valluri U; Sulowicz W
Adv Ther; 2021 Oct; 38(10):5361-5380. PubMed ID: 34537926
[TBL] [Abstract][Full Text] [Related]
19. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
Akizawa T; Yamaguchi Y; Majikawa Y; Reusch M
Ther Apher Dial; 2021 Oct; 25(5):575-585. PubMed ID: 33200512
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
Barratt J; Sulowicz W; Schömig M; Esposito C; Reusch M; Young J; Csiky B
Adv Ther; 2021 Oct; 38(10):5345-5360. PubMed ID: 34523074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
